EconPapers    
Economics at your fingertips  
 

Biotech-Pharmaceutical Alliances as a Signal of Asset and Firm Quality

Sean Nicholson, Patricia Danzon and Jeffrey S. McCullough

No 9007, NBER Working Papers from National Bureau of Economic Research, Inc

Abstract: Biotechnology companies rely heavily on alliances with pharmaceutical companies to finance their research and development expenditures, and pharmaceutical firms rely heavily on alliances to supplement their internal research and development. Previous studies suggest that asymmetric information may lead to inefficient contracting. We examine the determinants of biotech-pharmaceutical deal prices to determine whether the market for deals between biotech and pharmaceutical companies functions as a well-informed market or whether it is characterized by asymmetric information. We find that inexperienced biotech companies receive substantially discounted payments when signing their first deal. Drugs that are jointly developed are more likely to advance in clinical trials than drugs that are developed by a single company, so the first-deal discount is not consistent with the post-deal performance of these drugs. We also find that biotech companies that sign deals receive substantially higher valuations from venture capitalists and from the public equity market, which implies that the discounts are rational; a biotechnology company that is developing its first product benefits from forming an alliance with a pharmaceutical company because it sends a positive signal to prospective investors.

JEL-codes: I11 L24 (search for similar items in EconPapers)
Date: 2002-06
Note: CF HC
References: View references in EconPapers View complete reference list from CitEc
Citations: View citations in EconPapers (19) Track citations by RSS feed

Published as Sean Nicholson, 2005. "Biotech-Pharmaceutical Alliances as a Signal of Asset and Firm Quality," Journal of Business, University of Chicago Press, vol. 78(4), pages 1433-1464, July.

Downloads: (external link)
http://www.nber.org/papers/w9007.pdf (application/pdf)

Related works:
Journal Article: Biotech-Pharmaceutical Alliances as a Signal of Asset and Firm Quality (2005) Downloads
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:nbr:nberwo:9007

Ordering information: This working paper can be ordered from
http://www.nber.org/papers/w9007

Access Statistics for this paper

More papers in NBER Working Papers from National Bureau of Economic Research, Inc National Bureau of Economic Research, 1050 Massachusetts Avenue Cambridge, MA 02138, U.S.A.. Contact information at EDIRC.
Bibliographic data for series maintained by ().

 
Page updated 2019-12-04
Handle: RePEc:nbr:nberwo:9007